Sentences with phrase «dividend growth rate over»

Take TROW for example, it has a 15.2 % dividend growth rate over the past three years.

Pretty consistent with the dividend growth rate over the same time period, but the payout ratio (which is a bit elevated right now) would indicate that dividend growth over the next year or two might be more subdued.

-LSB-...] a 10.58 % CAGR dividend growth rate over the past 5 years, AAPL is up to a great start to become a Dividend Achiever in no -LSB-...]

The dividend growth rate over the last decade is a stout 7.5 %, which has actually been increasing with even higher dividend growth over the last five years.

The company has shown a very strong dividend growth rate over the past 5 years.

That's about what one would expect given Franklin's impressive dividend growth rate over the past decades.

If the company was able to sustain a 8 % dividend growth rate over the past 5 years and the payout ratios are still under 60 %, you can expect management to continue this pace for a while.

Its yield is good at 3.4 %, but its dividend growth rate over the past few years has been in the 2 % -3 % range per year.

The company has shown a very strong dividend growth rate over the past 5 years.

-LSB-...] a 10.58 % CAGR dividend growth rate over the past 5 years, AAPL is up to a great start to become a Dividend Achiever in no -LSB-...]

STORE's Dividend Growth Store has one of the fastest dividend growth rates over its short life, courtesy of its very strong pace of new property acquisition, which has translated into impressive growth in AFFO per share.

In David Fish's Dividend Champions list, you will find some companies with declining dividend growth rates over the past 10 years.

Not exact matches

I am pleased to announce that our Board of Directors declared a 7 % increase in our quarterly cash dividend to $ 0.77 per share, marking 14 consecutive years of dividend increases with a compound annual growth rate of about 10 % over that period.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

In addition, RTN appears to have a healthy, sustainable revenue growth rate of over 5 %, and the stock distributes a dividend of about 1.7 %.

This growth rate is the compound annual growth rate of cash dividends per common share of stock over the last 5 years.

There are a multitude of reasons as to why this occurs but it's a powerful enough force that many investors have done quite well for themselves over an investing lifetime by focusing on dividend stocks, specifically one of two strategies - dividend growth, which focuses on acquiring a diversified portfolio of companies that have raised their dividends at rates considerably above average and high dividend yield, which focuses on stocks that offer significantly above - average dividend yields as measured by the dividend rate compared to the stock market price.

A value over 1.0 suggests that the dividend growth rate has been increasing as the 5 year rate is higher than the 10 year rate.

This is meant to give you an idea of whether dividend growth rates are increasing or decreasing over time.

The following article will attempt to argue why younger investors should focus on growth stocks over dividend stocks in a bull market with potentially rising interest rates.

While you can find plenty of stocks with higher yields, General Dynamics» double - digit dividend growth rate implies that over time, investors could collect a much higher yield on cost.

7 Dividend growth is the annualized percentage rate of growth that a particular stock's dividend undergoes over a period Dividend growth is the annualized percentage rate of growth that a particular stock's dividend undergoes over a period dividend undergoes over a period of time.

• Stellar dividend resume: Decent yield at 2.9 %; excellent dividend growth rate of 20 % over the past 5 years; upcoming increase of 14 % in December; strong dividend safety, protected by very good cash flow; and 44 - year streak of increasing dividends.

As you can see on the above chart, earnings growth rates have been more variable than dividend payout rates over the last 120 years.

As I noted in the most recent Undervalued Dividend Growth Stock of the Week article on this stock, Enbridge grew its ACFFO at a compound annual rate of 7.94 % over the last ten fiscal years.

That's more than three - times the earnings growth rate at dividend - paying companies of 4.6 % over the same period.

If I assume a dividend growth rate of 6 percent (about the long - run average *), the current S&P 500 dividend yield of 2.1 percent (from multpl.com), a terminal S&P 500 dividend yield of 4 percent (Hussman says that the dividend yield on stocks has historically averaged about 4 percent), the expected nominal return over ten years is 2.4 percent annually.

Dividends per share have grown consistently over the past 7 years, but the rate of growth has slowed significantly over the most recent 3 year period.

These nearly zero interest rates is what drove many U.S. and European fixed income investors towards higher income opportunities in their own home countries — so, they bought more equities, REITs and dividend growth stocks over the last 5 years, driving up valuations (though the February correction has brought back some sanity.)

Revenues are forecasted to grow at an annual rate of 7 % over the next 5 years and when combined with a stock repurchase program it makes a dividend growth rate of 7 - 8 % annually very achievable.

For most of your holdings, insist on twenty years of dividend growth, an earnings growth rate of 5 % over the past ten years, and limited exposure to the financial sector.

While falling world interest rates have reduced the servicing cost of foreign debt over the past two years, this has been offset by rising dividend payments on foreign holdings of Australian equity, reflecting the strong profit growth of Australian companies throughout this period.

The yield is over 3 %, the growth rate is phenomenal, the payout ratio is a manageable 46 % and QCOM has increased the dividend 13 consecutive years.

John Bogle's modified version of the Gordon Equation (or the Dividend Discount Model) is that the total return from stocks equals the investment return plus the speculative return, where Investment Return = Dividend Yield + Earnings Growth Rate and Speculative Return = the change in the price to earnings ratio over the period examined.

Nucor's dividend growth rate was 1.61 % and 0.54 % over the last 10 years and 5 years, respectively.

Hi DM Patience and healthy dividend growth rates are very rewarding over time.

• Fast dividend growth rate at 20 % + over the past several years (offset by low yield).

For example, over five years is it just the average of the dividend growth rates for each year individually, or do you take the dividend at year 1 and compare it to the dividend in year 5?

OHI has raised their dividend just about every quarter over the past 5 years with an annual growth rate over 10 %.

Figures are also adjusted for changes in rates of earning and dividend growth, stability over a long term trend and cyclicality.

To maintain growth rates this high over any extended period, capital spending is required; for this reason, growth stocks tend to retain most of their earnings, paying little or no cash dividends.

The dividend was grown by more than nine percent a year over the last five years, but with the earnings growth rate being lower than that the dividend growth rate will decline somewhat in the long run.

The stock also has an attractive dividend yield of 3.6 %, a 10 % historical dividend growth rate, a reasonable earnings multiple (14x), and meaningful free cash flow growth potential over the next five years.

Over the last decade, the dividend growth rate has averaged 11.68 %.

I'm a dividend growth investor who is seeking passive dividend income that increases annually over the rate of inflation, and Intel just didn't seem to have my best interests in mind in regards to the dividend policy.

DIV STRK is consecutive years of dividend increases; DIV YLD is yield using the most recently announced dividend; 5 YR YLD is average dividend yield over the past 5 years; REC DG is most recent year - over-year dividend growth; 5 YR DG is average annual dividend growth over the past 5 years; PRICE was at market close Friday, March 2; FAIR VAL is Morningstar's «Fair Value Estimate»; FWD P / E is price / earnings ratio based on projected 2018 earnings; 5 YR P / E is average P / E ratio over the past 5 years; MOAT is Morningstar's rating of competitive economic advantage; SFT is Value Line's «Safety» score; CRD is Standard & Poor's credit rating; MKT CAP is market cap in billions of dollars.

And the growth over the last ten years has been blistering: the 10 - year dividend growth rate stands at a stout 17.1 %.

ACE's 5 - year compounded annual dividend growth rate (CADGR) is 15.40 %, making ACE one of the few companies that have doubled its dividend over the last 5 years.

• Stellar dividend resume: Decent yield at 2.9 %; excellent dividend growth rate of 20 % over the past 5 years; upcoming increase of 14 % in December; strong dividend safety, protected by very good cash flow; and 44 - year streak of increasing dividends.

That dividend growth has largely been fueled by excellent business growth, with Hanesbrands registering a compound annual growth rate of 17.42 % in its EPS over the last 10 fiscal years.